Eckert & Ziegler and Nucleus Radiopharma (Nucleus) signed extensive supply agreements for major therapeutic radioisotopes. Eckert & Ziegler will serve as core supplier for high-quality Lutetium-177 (Lu-177) as well as Actinium-225 (Ac-225), both in non-carrier-added form. Nucleus will use the radioisotopes to complement and advance their services for clinical development and manufacturing of radiopharmaceuticals.
While Eckert & Ziegler has successfully established a GMP-compliant production for Lu-177 in 2023 and is steadily upscaling the capacities, the manufacturing of larger quantities of GMP-grade Ac-225 is expected to start in 2024.
To read more please visit:
Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177
Source: Eckert